Bath University spinout Atlas Genetics gains approval to sell its rapid chlamydia test within the EU.

Mitsui-backed Chi-Med, listed in the UK since 2006, will put the money towards advancing its seven clinical-stage drug candidates.

Agilent has acquired a 48% stake in genome sequencing company Lasergen and secured a two-year option to buy the remaining shares for another $105m.

Existing investors Amgen and Astellas participated in a round that lifted the immuno-oncology treatment developer's total financing to $70m.

Intel Capital, an investor since 2011, achieved an exit in a Chinese IPO, and has now exited a quarter of its 120 China-based portfolio companies.

Laurent Audoly, managing partner of the pharmaceutical company's new open innovation scheme, spoke to Global Corporate Venturing about its collaboration and investment strategy.

Jianmin, Ping An and InCube Labs all contributed to a round that will fund phase 1 clinical trials for Fe3 Medical's iron deficiency patch.

Johnson & Johnson has opened its fifth JLabs incubator in the US at the Texas Medical Centre, launching with an initial 21 startups.

The biopharma tools developer secured $25m in a Novo-led series A round in February last year.